Bone marrow damage may explain why the body cannot heal Alzheimer's on its own

A groundbreaking study published in the journal *Nature Neuroscience* has identified a critical failure in the body’s internal defence mechanism, suggesting that damage to bone marrow may be a primary reason why the human body cannot naturally heal from Alzheimer’s disease. For decades, the scientific community has concentrated its efforts almost exclusively on the brain, focusing on the accumulation of misfolded proteins, specifically amyloid-beta plaques and tangled tau proteins. However, this new research indicates that some of the most significant pathological damage occurs far from the cranium, within the spongy tissue of the bone marrow, where the body’s stem cells reside.

Bone marrow serves as the vital factory for the body’s immune system, housing stem cells that differentiate into specialised immune cells tasked with healing damaged tissue. Previous research had already established that immune cells originating in the bone marrow act as essential reinforcements for the brain’s resident immune cells, known as microglia. As microglia become exhausted over the course of the disease and lose their efficiency in clearing amyloid plaques, these bone marrow-derived reinforcements are intended to step in, reduce neuroinflammation, and slow the progression of cognitive decline. Despite this knowledge, the specific identity of these cells and the mechanisms governing their migration to the brain remained a significant mystery in neurodegenerative research.

In this latest study, researchers have successfully identified that the development of monocytes—a specific type of white blood cell—is fundamentally impaired in both mouse models of Alzheimer’s and in human patients. The study highlights that in healthy subjects, a substantial fraction of bone marrow stem cells maintain the capacity to replenish the immune system over the long term. Conversely, in mice afflicted with Alzheimer’s, this self-renewal ability is lost. The stem cells were observed to mature prematurely into specialised cells, and the biological process responsible for generating monocytes was visibly and significantly impaired. The researchers noted that a similar phenotype was present in the circulating monocytes of human Alzheimer’s patients, suggesting a consistent biological failure across species.

Furthermore, the research reveals that Alzheimer’s disease disrupts the critical immune alarm signal that normally instructs the bone marrow to dispatch monocyte reinforcements to the brain. The study authors noted that the factors limiting the spontaneous homing of these cells to the diseased brain had previously been unclear, but this disruption of the signalling pathway provides a compelling explanation. When the scientists employed a targeted therapy to restore the bone marrow process behind monocyte production in mice, they observed that the disease pathology was notably ameliorated. This improvement was directly linked to an increased homing of monocyte-derived macrophages to the brain, effectively bolstering the brain's ability to combat the disease.

These findings suggest that in patients suffering from Alzheimer’s, the self-renewal capacity of stem cells is exhausted prematurely, manifesting as signs of accelerated ageing within the blood system. This discovery adds substantial weight to a growing body of evidence suggesting that Alzheimer’s is not merely a localised brain condition, but rather a systemic, body-wide disease. While the researchers caution that the work was largely conducted in mice and that translating these findings into human clinical therapies will require extensive further study, the identification of bone marrow dysfunction as a potential therapeutic target represents a major shift in perspective. By moving beyond the traditional focus on brain pathology alone, this research opens a promising new avenue for the development of treatments that could one day restore the body’s own ability to fight this devastating condition.